Moving the Goal Post: Multidisciplinary Management of Advanced NSCLC

Slides:



Advertisements
Similar presentations
Fostering a Collaborative Approach in the Management of BRCA-Mutated Ovarian Cancer.
Advertisements

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
Systemic Lupus Erythematosus
Treatment Algorithms in Melanoma: Past, Present, and Future
T-Cell Exhaustion: Can We Overcome It in Cancer?
Advances in Managing Inhibitors in Patients With Hemophilia A
Fundamental Concepts in the Diagnosis of Advanced NSCLC
Assessing the Impact: New Data in T790+ NSCLC
Progression After Cancer Immunotherapy in Advanced NSCLC
The HCV Revolution: Are You and Your Practice Ready?
Standards of Care in Duchenne Muscular Dystrophy: A 2018 Update
New Standards of Care in ALK-Translocated Advanced NSCLC
Advances in Cystic Fibrosis 2017
Induction Chemotherapy for Patients With High-Risk or Secondary AML
Introduction. For Pulmonologists by Pulmonologists: Diagnosis of NSCLC in an Age of Biomarkers.
The Resurgence of Topical Treatments Across a Spectrum of Psoriasis
Aligning Patients and Clinicians: Optimizing Outcomes in Metastatic NSCLC.
Navigating the Data and Evolving Our Approach
Addressing Disease Burden in Asthma
The Evolving Role of Immunotherapy in NSCLC
Optimizing Management of Advanced Bladder Cancer
Management Challenges in CLL
Multidisciplinary Perspectives on Interstitial Lung Diseases
The Emerging Role of Immunotherapy in Hodgkin Lymphoma
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
Next-Gen Psoriasis Therapies:
Case Studies in Unresectable Hepatocellular Carcinoma
Hyperhidrosis Is Burdensome!
Navigating New Oral Treatment Algorithms in CLL
Optimizing Outcomes and Managing Adverse Events in CLL
Immunotherapy for cSCC
EGFR-Mutated NSCLC and CNS Involvement: the Conundrum
Expert Insights Into the Latest Treatment of Advanced Soft-Tissue Sarcoma.
Personalizing Management in the Care of Patients With Advanced Sarcoma
Evolving Concepts in the Management of Head and Neck Cancers
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
Parkinson Disease Psychosis
Talking With Your Patients About Excessive Sweating
Immune Checkpoint Inhibitors in Lung Cancer
Advances in Severe Asthma Management
Guide to Atopic Dermatitis
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
Defining Patient-Centered Care: Spotlight on Advanced Non-Small Cell Lung Cancer.
Patient Questions and Expert Answers in Psoriasis:
Biomarker Testing: Harnessing All Sides of the Tumor Microenvironment
All for One: Multidisciplinary Management in EGFR-Mutated NSCLC
Challenges and Opportunities
This program will include a discussion of off-label treatment and investigational agents not approved by the Food and Drug Administration for use in the.
Novel Concepts in the Management of RCC
Debates and Dilemmas, Part 1
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data.
This program will include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a.
From Adjuvant to Metastatic in Melanoma
Multidisciplinary Management in Non-Small Cell Lung Cancer (NSCLC)
Optimizing Characterization of NSCLC Through Specialty Collaboration
Immune Checkpoint Inhibitors in EGFR-Mutated NSCLC
The Nurse View: Spotlight on Immune Checkpoint Inhibitors in Advanced Lung Cancer.
Prioritizing Prevention of HPV-Related Disease
Case Studies in Locally Advanced Pancreatic Cancer
Peanut Allergy Immunotherapy
Optimizing Outcomes in mRCC: Finding the Balance of Immune Inhibition
This program will include a discussion of off-label treatment or use of investigational agents not approved by the FDA for use in the US, and data that.
Checkpoint Inhibitors in First-Line Advanced NSCLC
Peanut Allergy Immunotherapy
The Nurse View: Spotlight on EGFR-Mutated NSCLC
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
Finding the Right Sequence in Patients With EGFR-Mutated NSCLC
Next-Generation Sequencing and ctDNA
Immune Checkpoint Inhibitors in Lung Cancer
Comparative Studies of Biologics in Ulcerative Colitis
Presentation transcript:

Moving the Goal Post: Multidisciplinary Management of Advanced NSCLC

This program will include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

Patient Case

Multidisciplinary Team Structure

Diagnosis and Biopsy

Biopsy Options For Patients With Localized Disease

Use of Samples For Testing

Testing Specifics

Options When There Is Limited Tissue Availability

Patient Case (cont)

Algorithm For Front-Line Treatment in Advanced NSCLC

Front-Line Treatment Options In the Absence of Targetable Mutations

Continuation of Multidisciplinary Care

Second-Line PD-L1 Testing Considerations

Second-Line Treatment Options In the Absence of Targetable Mutations

Communication Between Multidisciplinary Team Members

The Patient Is a Team Member

Tips For Community Providers

Concluding Remarks

Abbreviations

Abbreviations (cont)